Abstract
Despite an abundance of evidence to the contrary from animal studies, large clinical trials on humans have shown that estrogen administered to postmenopausal women increases the risk of cardiovascular disease. However, timing may be everything, as estrogen is often administered immediately after ovariectomy (Ovx) in animal studies, while estrogen administration in human studies occurred many years postmenopause. This study investigates the discrepancy by administering 17β-estradiol (E2) in a slow-release capsule to Norway Brown rats both immediately following Ovx and 9 wk post-Ovx (Late), and studying differences in gene expression between these two groups compared with age-matched Ovx and sham-operated animals. Two different types of microarray were used to analyze the left ventricles from these groups: an Affymetrix array (n = 3/group) and an inflammatory cytokines and receptors PCR array (n = 4/group). Key genes were analyzed by Western blotting. Ovx without replacement led to an increase in caspase 3, caspase 9, calpain 2, matrix metalloproteinase (MMP)9, and TNF-α. Caspase 6, STAT3, and CD11b increased in the Late group, while tissue inhibitor of metalloproteinase 2, MMP14, and collagen I α1 were decreased. MADD and fibronectin were increased in both Ovx and Late. TNF-α and inducible nitric oxide synthase (iNOS) protein levels increased with Late replacement. Many of these changes were prevented by early E2 replacement. These findings suggest that increased expression of inflammatory genes, such as TNF-α and iNOS, may be involved in some of the deleterious effects of delayed E2 administration seen in human studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1065-1073 |
| Number of pages | 9 |
| Journal | Physiological Genomics |
| Volume | 43 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 2011 |
Fingerprint
Keywords
- Cardiovascular disease
- Timing hypothesis
ASJC Scopus subject areas
- Physiology
- Genetics
Cite this
Impact of aging vs. estrogen loss on cardiac gene expression : Estrogen replacement and inflammation. / Pechenino, Angela S.; Lin, Li; Mbai, Fiona N.; Lee, Alison R.; He, Xian Min; Stallone, John N.; Knowlton, Anne A.
In: Physiological Genomics, Vol. 43, No. 18, 09.2011, p. 1065-1073.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of aging vs. estrogen loss on cardiac gene expression
T2 - Estrogen replacement and inflammation
AU - Pechenino, Angela S.
AU - Lin, Li
AU - Mbai, Fiona N.
AU - Lee, Alison R.
AU - He, Xian Min
AU - Stallone, John N.
AU - Knowlton, Anne A
PY - 2011/9
Y1 - 2011/9
N2 - Despite an abundance of evidence to the contrary from animal studies, large clinical trials on humans have shown that estrogen administered to postmenopausal women increases the risk of cardiovascular disease. However, timing may be everything, as estrogen is often administered immediately after ovariectomy (Ovx) in animal studies, while estrogen administration in human studies occurred many years postmenopause. This study investigates the discrepancy by administering 17β-estradiol (E2) in a slow-release capsule to Norway Brown rats both immediately following Ovx and 9 wk post-Ovx (Late), and studying differences in gene expression between these two groups compared with age-matched Ovx and sham-operated animals. Two different types of microarray were used to analyze the left ventricles from these groups: an Affymetrix array (n = 3/group) and an inflammatory cytokines and receptors PCR array (n = 4/group). Key genes were analyzed by Western blotting. Ovx without replacement led to an increase in caspase 3, caspase 9, calpain 2, matrix metalloproteinase (MMP)9, and TNF-α. Caspase 6, STAT3, and CD11b increased in the Late group, while tissue inhibitor of metalloproteinase 2, MMP14, and collagen I α1 were decreased. MADD and fibronectin were increased in both Ovx and Late. TNF-α and inducible nitric oxide synthase (iNOS) protein levels increased with Late replacement. Many of these changes were prevented by early E2 replacement. These findings suggest that increased expression of inflammatory genes, such as TNF-α and iNOS, may be involved in some of the deleterious effects of delayed E2 administration seen in human studies.
AB - Despite an abundance of evidence to the contrary from animal studies, large clinical trials on humans have shown that estrogen administered to postmenopausal women increases the risk of cardiovascular disease. However, timing may be everything, as estrogen is often administered immediately after ovariectomy (Ovx) in animal studies, while estrogen administration in human studies occurred many years postmenopause. This study investigates the discrepancy by administering 17β-estradiol (E2) in a slow-release capsule to Norway Brown rats both immediately following Ovx and 9 wk post-Ovx (Late), and studying differences in gene expression between these two groups compared with age-matched Ovx and sham-operated animals. Two different types of microarray were used to analyze the left ventricles from these groups: an Affymetrix array (n = 3/group) and an inflammatory cytokines and receptors PCR array (n = 4/group). Key genes were analyzed by Western blotting. Ovx without replacement led to an increase in caspase 3, caspase 9, calpain 2, matrix metalloproteinase (MMP)9, and TNF-α. Caspase 6, STAT3, and CD11b increased in the Late group, while tissue inhibitor of metalloproteinase 2, MMP14, and collagen I α1 were decreased. MADD and fibronectin were increased in both Ovx and Late. TNF-α and inducible nitric oxide synthase (iNOS) protein levels increased with Late replacement. Many of these changes were prevented by early E2 replacement. These findings suggest that increased expression of inflammatory genes, such as TNF-α and iNOS, may be involved in some of the deleterious effects of delayed E2 administration seen in human studies.
KW - Cardiovascular disease
KW - Timing hypothesis
UR - http://www.scopus.com/inward/record.url?scp=80053163686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053163686&partnerID=8YFLogxK
U2 - 10.1152/physiolgenomics.00228.2010
DO - 10.1152/physiolgenomics.00228.2010
M3 - Article
C2 - 21750230
AN - SCOPUS:80053163686
VL - 43
SP - 1065
EP - 1073
JO - Physiological Genomics
JF - Physiological Genomics
SN - 1094-8341
IS - 18
ER -